- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Melanoma
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 1.1MB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 779KB)
Relatlimab with nivolumab – July 2022
Relatlimab with nivolumab: Injection concentrate for I.V. infusion containing 80 mg relatlimab and 240 mg nivolumab in 20 mL; Opdualag®
Last updated
11 November 2022